Apnimed to Present Data on Drug Candidate for Sleep Apnea
Data from Apnimed’s MARIPOSA phase 2b trial of its drug candidate for OSA will be featured at the ATS 2023 International Conference.
Source: sleepreviewmag.com
Stay updated with breaking news from Huy Pho. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from Apnimed’s MARIPOSA phase 2b trial of its drug candidate for OSA will be featured at the ATS 2023 International Conference.
In a new study with obese mice, Johns Hopkins Medicine researchers say they have added to evidence that specialized channel proteins are possible therapeutic targets for sleep apnea and similar abnormally slow breathing disorders in obese people.